FLT3 and acute myeloid leukemia: In more than 30% of FLT3-mutated r/r AML patients treated with gilteritinib, several new mutations in genes involved in the RAS/MAPK pathway were detected by targeted next-generation sequencing with NRAS being the most common mutation finding [33].